What Do Analysts Think About Gilead Sciences (GILD)?

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable growth stocks to buy. In a report released on August 21, Evan Seigerman from BMO Capital reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), setting a price target of $130.00.

Similarly, Bernstein raised the firm’s price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $135 from $120 on August 20, keeping an Outperform rating on the shares.

The firm told investors in a research note that Gilead Sciences, Inc. (NASDAQ:GILD) reported EPS and Q2 revenue slightly above estimates, with the full year guidance raised as HIV performed better than expected.

Gilead Sciences, Inc. (NASDAQ:GILD) has a Strong Buy analyst consensus rating, with its median price target of $112.97 implying an upside of 14.19% from current levels.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.